Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multiplex IHC methods offer limited understanding of the complex TME. This is partially due to technical limitations of chromogenic dyes and fluorescent detection systems.
Senior Principal Scientist, Boehringer Ingelheim Pharmaceuticals
Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the analysis of target protein expression in subsets of specific cells within the context of histopathological features of disease.
PhD, Image Analysis Specialist for Leica Biosystems Aperio ePathology
An unmet need in tissue diagnostics is the ability to simultaneously detect three or more markers on a single tissue specimen, i.e. multiplexing. Unlike other immunoassays, i.e. flow cytometry, ELISA and bead assays, which solely quantify the biomarker in a sample, a multiplex immunoassay quantifies the biomarker, identifies the location of the cell in the tissue and identifies the spatial relationship of the biomarkers with respect to each other.
In this webinar, we will discuss how Akoya Biosciences Phenoptics assays support quantitative mIF to overcome the limitations imposed by conventional IHC methodologies. We will also discuss how our Opal assay kits and reagents can be integrated with the Leica
In this webinar, we will cover biological and technical considerations when designing a panel, a linear process for developing, testing, and optimizing a panel, and an approach for technical validation of multiplex panels which detects and addresses known risks.
The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high-quality specific results compared to spurious, non-specific antibody staining on tissue will be easier and allow the researcher to focus on downstream applications, such as single and multiplex IHC.